Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Elevation Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
21.03. | Elevation Oncology Plunges 42% on Ending Development of Lead Drug | 4 | Zacks | ||
21.03. | Elevation Oncology downgraded as it halts lead asset on disappointing trials | 1 | Investing.com | ||
21.03. | Elevation Oncology stock rating cut amid ADC asset halt | 1 | Investing.com | ||
21.03. | Piper Sandler cuts Elevation Oncology stock rating to Neutral | 2 | Investing.com | ||
20.03. | Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70% | 1 | Benzinga.com | ||
20.03. | Elevation Oncology slumps on plans to drop cancer candidate | 2 | Seeking Alpha | ||
20.03. | Why Is Elevation Oncology Stock Falling In Pre-market? | - | RTTNews | ||
ELEVATION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
20.03. | Elevation Oncology stock tumbles on halted drug development | 1 | Investing.com | ||
19.03. | Elevation Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
10.03. | H.C. Wainwright maintains Buy on Elevation Oncology stock | 1 | Investing.com | ||
10.03. | Elevation Oncology stock holds $7 target at JMP Securities | 2 | Investing.com | ||
06.03. | Elevation Oncology GAAP EPS of -$0.18 beats by $0.04 | 2 | Seeking Alpha | ||
06.03. | Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements | 48 | PR Newswire | -- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced... ► Artikel lesen | |
06.03. | Elevation Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
06.03. | Elevation Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
31.01. | Elevation Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.01. | Elevation Oncology advances gastric cancer trial, eyes new data in 2025 | 9 | Investing.com | ||
13.01. | Elevation Oncology erzielt Fortschritte bei Magenkrebs-Studie und plant neue Daten für 2025 | 2 | Investing.com Deutsch | ||
13.01. | Elevation Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 24,025 | -6,01 % | Impfstoff-Aktien Moderna, BioNTech und Co massiv unter Druck - Gegenwind in den USA | Auch zum Start in die neue Handelswoche bahnen sich erneut Kursverluste bei einigen US-gelisteten Aktien aus dem Pharma- und Biotech-Sektor an. Vor allem bei den Impfstoff-Titeln geht es teilweise kräftig... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,492 | +0,20 % | Palatin: Bremelanotide-Tirzepatide Combination Achieves Primary Endpoint In Phase 2 Obesity Study | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The... ► Artikel lesen | |
BIOXXMED | 0,800 | +107,25 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
ORGANOVO | 2,140 | 0,00 % | Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
OCUGEN | 0,597 | -6,14 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA ZSB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSIRONA BIOCHEM CORP.... ► Artikel lesen | |
BIO-GATE | 0,760 | 0,00 % | Bio-Gate: Vielversprechende Wachstumschancen | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im Geschäftsjahr 2024 (per 31.12.) einen leichten Umsatzrückgang verbucht, besitzt aufgrund der innovativen... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,662 | -5,43 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
VAXART | 0,347 | +6,17 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
TEMPUS AI | 46,630 | -6,53 % | Tempus AI, Inc. (NASDAQ:TEM) Sees Significant Increase in Short Interest | ||
CELLECTAR BIOSCIENCES | 0,280 | -0,71 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
BURCON NUTRASCIENCE | 0,059 | -0,67 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
AFFIMED | 0,930 | -100,00 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting | MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
IMMUNIC | 0,943 | -8,27 % | EQS-News: Immunic AG: Immunic, Inc. to Participate in Scientific and Industry Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
01.04.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
AIM IMMUNOTECH | 0,105 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over... ► Artikel lesen |